Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of ElsaLys Biotech.

    Client Virtual Booth

    ELSALYS BIOTECH

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    ElsaLys Biotech
    France Flag
    Country
    Country
    France
    Address
    Address
    317 Avenue Jean Jaurès, 69007 Lyon
    Telephone
    Telephone
    +33 (0)4 37 28 73 00
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.elsalysbiotech.com/home/home
    Linkedin
    Linkedin
    https://www.linkedin.com/company/elsalys-biotech/
    Twitter
    Twitter
    https://twitter.com/elsalys_biotech

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Elsalys Confirms The Renew of Its Cohort Atu in France and Compassionate Use Programs Submissions in Several Other Countries for Inolimomab

    Details:

    ElsaLys Biotech confirmed that The French National Agency for the Medicines and Health Products Safety (ANSM) has renewed the Temporary Authorisation for Use (ATU) so-called cohort ATU (cATU) for inolimomab (LEUKOTAC®) on December 24, 2020.


    Lead Product(s): Inolimomab

    Therapeutic Area: Immunology Product Name: Leukotac

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 14, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Consortium Including ElsaLys Biotech and Novadiscovery Awarded €3.35 Million by Bpifrance to Advance Inolimomab in Graft-Versus-Host Disease

    Details:

    The Silikotac Program consortium, consisting of ElsaLys Biotech, Novadiscovery and two expert academic teams, has been awarded €3.35 million in non-dilutive funding by Bpifrance to support development of inolimomab in graft-versus-host disease.


    Lead Product(s): Inolimomab

    Therapeutic Area: Immunology Product Name: Leukotac

    Highest Development Status: ApprovedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Bpifrance

    Deal Size: $4.0 million Upfront Cash: Undisclosed

    Deal Type: Funding January 19, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    ElsaLys Biotech Submits Biologics License Application to FDA for LEUKOTAC for the treatment of graft-versus-host disease in adult patients

    Details:

    Inolimomab has shown a robust and long-lasting response Rate in steroid-refractory acute graft versus host disease (SR-aGvHD) in a randomized multicentre controlled parallel-group Phase 3 study (INO-107 - EUDRACT 2007-005009-24).


    Lead Product(s): Inolimomab

    Therapeutic Area: Immunology Product Name: Leukotac

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 23, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Mediolanum Farmaceutici Acquires the French Company ElsaLys Biotech to Develop Next Generation Immuno-oncology Therapies

    Details:

    Acquisition of ElsaLys Biotech adds drugs like Inolimomab and ELB011 to Mediolanum Farmaceutici's pipeline paving the way for its international expansion and increasing the Group's R&D capabilities.


    Lead Product(s): Inolimomab

    Therapeutic Area: Immunology Product Name: Undisclosed

    Highest Development Status: Phase IIIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Mediolanum Farmaceutici

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition May 07, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search